ストックスクリーナーアプリを入手
0.9865
8.89%
0.0805
アフターアワーズ：
.94
-0.0465
-4.71%
Promis Neurosciences Inc (PMN) 最新ニュース
What drives ProMIS Neurosciences Inc. stock priceMassive portfolio appreciation - PrintWeekIndia
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR) - The Globe and Mail
ProMIS Neurosciences Inc. Stock Analysis and ForecastExplosive earnings growth - Autocar Professional
What analysts say about ProMIS Neurosciences Inc. stockAccelerated earnings growth - PrintWeekIndia
When is the best time to buy ProMIS Neurosciences Inc. stockHigh-impact stock picks - jammulinksnews.com
Is ProMIS Neurosciences Inc. stock a growth or value playFree Predictions - jammulinksnews.com
Will ProMIS Neurosciences Inc. stock split in the near futureConsistent triple-digit returns - jammulinksnews.com
ProMIS Neurosciences Gains FDA Fast Track for PMN310 - The Globe and Mail
Is ProMIS Neurosciences Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com
Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize
Still undervalued? ProMIS Neurosciences keeps $9.50 target price at Leede - Cantech Letter
Alzheimer’s stock triples after FDA Fast-Track Designation - MSN
ProMIS Neurosciences Plunges 24.56% Intraday—Is the FDA Fast Track Outpacing Investor Sentiment? - AInvest
ProMIS Neurosciences Plunges 28% Intraday—Is This the Catalyst No One Saw Coming? - AInvest
What makes ProMIS Neurosciences Inc. stock price move sharplyBreakout Level Watch - Newser
Buy Rating for ProMIS Neurosciences Driven by Fast Track Designation and Promising Alzheimer’s Treatment Potential - TipRanks
ProMIS Neurosciences Announces Private Placement Financing - GlobeNewswire
ProMIS Neurosciences announces $0.8M registered direct offering - TipRanks
ProMIS Neurosciences announces private placement financing - TipRanks
ProMIS Neurosciences stock gets FDA Fast Track designation for PMN310 - Investing.com
ProMIS Neurosciences (PMN) Secures Funding to Enhance Therapeuti - GuruFocus
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules - The Manila Times
ProMIS Neurosciences Announces Private Placement Financing | PMN Stock News - GuruFocus
ProMIS Neurosciences Announces $2.4 Million PIPE Financing for Clinical Development of PMN310 - Nasdaq
ProMIS Neurosciences Drops 9.82% Amid ICICI Bank's Strong Earnings - AInvest
ProMIS Secures $9.2M Funding Boost: Accelerates Novel Alzheimer's Treatment Development - Stock Titan
ProMIS Neurosciences ends at-the-market agreement and receives FDA fast track for PMN310 - Investing.com Australia
3 Penny Stocks to Watch Now, 7/22/25 - TipRanks
ProMIS Neurosciences Inc Inc. (PMN) Price Performance: The Role of Supply and Demand - investchronicle.com
ProMIS Neurosciences shares surge 149.77% intraday after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
Shares Of Micro Cap Biotech Surge After Breakthrough FDA Designation - The Globe and Mail
Alzheimer’s stock triples after FDA Fast-Track Designation | 2025-07-21 | Investing News - Stockhouse
ProMIS Neurosciences Soars 134%—What’s Fueling This Biotech Breakout? - AInvest
ProMIS Neurosciences (PMN) up more than 300% since Jul 8 - AInvest
Promis Neurosciences shares surge 250% intraday after FDA grants Fast Track designation for PMN310 Alzheimer's treatment. - AInvest
ProMIS Neurosciences: Stock Surge Insight - StocksToTrade
ProMIS Neurosciences Soars 157% on FDA Fast Track Designation – What’s Fueling This Volatile Rally? - AInvest
ProMIS Neurosciences stock soars after FDA grants Fast Track for Alzheimer’s drug - Investing.com
ProMIS Neurosciences Surges: Analyzing Recent Moves - timothysykes.com
ProMIS Neurosciences shares surge 21.37% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310 - MSN
Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today? - TipRanks
ProMIS Neurosciences shares surge 17.50% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
Why ProMIS Is Rising In Pre-market? - Nasdaq
FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug By Investing.com - Investing.com South Africa
FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug - Investing.com Australia
ProMIS Neurosciences granted Fast Track designation by FDA for PMN310 - TipRanks
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):